Updates are available Correction dated 2020-06-18
Click to view Correction: https://doi.org/10.1038/s41591-020-0978-1
-
Authors
Brastianos, Priscilla K. https://orcid.org/0000-0003-4470-8425
Lee, Eudocia Quant
Cohen, Justine V.
Tolaney, Sara M.
Lin, Nancy U.
Wang, Nancy
Chukwueke, Ugonma
White, Michael D. https://orcid.org/0000-0002-3855-9243
Nayyar, Naema
Kim, Albert
Alvarez-Breckenridge, Christopher
Krop, Ian
Mahar, Maura Keeley
Bertalan, Mia S.
Shaw, Brian
Mora, Joana L.
Goss, Nathaniel
Subramanian, Megha
Nayak, Lakshmi
Dietrich, Jorg
Forst, Deborah A.
Nahed, Brian V.
Batchelor, Tracy T.
Shih, Helen A.
Gerstner, Elizabeth R.
Moy, Beverly
Lawrence, Donald
Giobbie-Hurder, Anita
Carter, Scott L. https://orcid.org/0000-0002-8480-1475
Oh, Kevin
Cahill, Daniel P.
Sullivan, Ryan J. https://orcid.org/0000-0001-5344-6645
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
Merck
Massachusetts General Hospital
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA227156-01, 5R21CA220253-02, 1R01CA244975-01, 1R01CA244975-01, 1R01CA244975-01, 5R21CA220253-02, 1R01CA227156-01)
Damon Runyon Cancer Research Foundation
Melanoma Research Alliance
American Brain Tumor Association
- License Information
-
More Information
Article History
Received: 30 August 2019
Accepted: 1 May 2020
First Online: 2 June 2020
Change Date: 18 June 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-020-0978-1
Competing interests
: P.K.B. has consulted for Tesaro, Angiochem, Genentech-Roche, ElevateBio and Eli Lilly, has received institutional research funding (to Massachusetts General Hospital) from Merck, Eli Lilly, BMS and Pfizer and has received honoraria from Merck and Genentech-Roche. J.C. has received consulting fees from Sanofi-Genzyme and BMS. D.P.C. has consulted for Eli Lilly and Boston Pharmaceuticals and has received travel and speaking fees from Merck. S.M.T. receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odenate and Nektar. S.M.T. has served as an advisor and consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Tesaro, Daiichi Sankyo, Athenex, Sanofi, Bristol Meyers Squibb and Nanostring. N.U.L. has received institutional research funding from Seattle Genetics, Genentech, Merck and Pfizer. N.U.L. has also served on an advistory board or consulted for PUMA Biotechnology, Seattle Genetics and Daichii Sankyo. R.J.S. has received research funding from Amgen and Merck and has served as a paid consultant and/or been on an advisory board for Array BioPharma, Amgen, Asan Biosciences, BMS, Compugen, Genentech, Merck, Novartis and Replimmune. E.Q.L. has received royalties from Wolters Kluwers (UpToDate, Inc) and has consulted for Eli Lilly. B.M. has received institutional research funding from PUMA Biotechnology. D.A.F. is an Eli Lilly shareholder. I.K. has received personal fees for being a member of a Merck DSMC, has received research funding from Genentech and Pfizer and has served as a paid consultant and/or been on an advisory board for Genentech, Bristol Meyers Squibb, Daiichi/Sankyo, Macrogenics and AstraZeneca. T.T.B. is on the Scientific Advisory Board for Genomicare. M.D.W. is a consultant at Boston Pharmaceuticals. Dana-Farber Cancer Institute has a financial interest in pembrolizumab and has taken steps to manage any actual or potential conflict of interest created by this financial interest, which was described in the information sheet available to all participants in this study.
